Karuna Therapeutics (KRTX): Market Cap to Earnings and Growth Ratio

Symbol and logo of brand Karuna Pharma (KRTX)

Automating molecule screening in laboratories optimizes expenses, which supports the upward trend. The P/E growth potential metric visualizes the balance between price and expansion, where the value 0.00 shows the current magnitude. The foundation of Karuna Therapeutics (KRTX) relies on exclusive psychiatric patents under FDA supervision, and the commercial launch of an innovative antipsychotic is rapidly increasing the company's current revenue.

Karuna Therapeutics (KRTX): Price/Earnings to Growth Multiple from 07/04/2022 to 03/23/2024

Analytical breakdowns for Karuna Therapeutics, Inc. (KRTX)

- share price and consensus valuation forecast:
Price Performance Chart Karuna Pharma|KRTX - Price Target Chart
- stock exchange capitalization data:
Market Valuation Karuna Therapeutics|KRTX - Total Company Value
- balance sheet net asset value indicators:
Net Assets per Share Karuna Therapeutics|KRTX - Company Net Assets|Market-to-Book Ratio karunatx.com|KRTX - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Equity Ratio Karuna Therapeutics|KRTX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Karuna Therapeutics Inc|KRTX - Company Debts|Debts to Book Value Karuna Therapeutics|KRTX - Company Long-Term Debt|Company Short-Term Debts Karuna Therapeutics|Quick Ratio karunatx.com
- net income and valuation ratios data:
KRTX - Company Net Income|Expected Net Income Karuna Therapeutics|KRTX - Price to Earnings Ratio|Forward P/E Multiple karunatx.com|KRTX - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Karuna Pharma|KRTX - Operating profit EBITDA|Net earnings per share (EPS TTM) Karuna Therapeutics|KRTX - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months karunatx.com|KRTX - Net earnings per share growth this year|Projected earnings per share increase next year Karuna Therapeutics
- sales revenue and business income indicators:
KRTX - Revenue and Sales Volume|Company Future Revenue Karuna|KRTX - P/S Multiple|Market Cap to Future Revenue Ratio Karuna Therapeutics
Fundamental company analysis:KRTX - Karuna Pharma
Original product of karunatx.com

This metric compares the current market earnings multiple with growth rates, allowing investors to determine if they are overpaying for the business's future success. Analyzing the PEG ratio for Karuna Therapeutics (KRTX) is critical, as exclusive patents and stringent FDA oversight create high volatility in expectations regarding the commercialization of psychotropic drugs.

Competitors of Karuna Therapeutics

ALKS (Alkermes Corp) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Avadel Pharma AVDL|ATAI (atai.life) - Market Cap to Earnings and Growth Ratio|GHRS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income MindMed Inc. MNMD|CMPS (compasspathways.com) - Price/Earnings to Growth Multiple|Price to Earnings Adjusted for Growth Rate LB Pharma (LBRX)|DRUG (brightmindsbio.com) - PEG Multiple|Price/Earnings to Growth Multiple Vanda Pharmaceuticals (VNDA)|PEG Multiple CYBN|ANRO (Alto Neuroscience Inc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio nrxpharma.com NRXP|Cingulate Corp (CING) - Price to Earnings Adjusted for Growth Rate|SILO - Price/Earnings to Growth Ratio|chinapharmaholdings.com (CPHI) - Price/Earnings to Growth Multiple|Clearmind Medicine (CMND) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate Psyence Biomedical (PBM)|SPRC (SciSparc Corp) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Seelos Therapeutics Inc SEEL|Price/Earnings to Growth Ratio virpaxpharma.com (VRPX)